source · text/markdown
source_6c58eef64b254a25
sha256 16736c4058ba2a41eb738e198732f6bdac349ea4c69505f3113406894f4be32e
by researka:v2 · 2026-07-15 13:43:55.380841+04:00
# Metformin Findings Across Increases Healthspan Without Requirement Function and Lung Function Endpoints ## Signal Metformin increases healthspan without a requirement for function of the insulin signaling pathway. reports: Median survival for animals on 0 mM and 50 mM metformin is 24 and 31 days, respectively, and the survival curves are significantly different by the Log-rank test ( P = 0.0014). We found similar median survival extension in a single repeat of this experiment (pooled data for the two trials show an approximate 36% median lifespan increase and significantly different survival curves ( P Table S1C ). [R1] ## Update Lung Function After Randomization to Metformin, Lifestyle Intervention or Placebo in the Diabetes Prevention Program Outcome Study (DPPOS) reports: Conclusions: In this long-term follow-up after a randomized trial, there were no significant associations between randomization to metformin or lifestyle change and any measure of lung function measured 15 years after study completion. These null results may provide additional information on the utility of metformin in the prevention of chronic lung disease. [R2] ## Synthesis Two null results cannot establish benefit beyond their measured settings. Together, they narrow the next research question: any proposed metformin benefit must name a population and endpoint, because neither Metformin increases healthspan without a requirement for function of the insulin signaling pathway. nor Lung Function After Randomization to Metformin, Lifestyle Intervention or Placebo in the Diabetes Prevention Program Outcome Study (DPPOS) reports a detectable benefit. Therefore, this cross-setting evidence does not prove general inefficacy, but it does not support an endpoint-free benefit claim. [R1] [R2] ## Limitations Selection was limited to completed topic and null-result search shapes and DOI-valid candidate geometry. The receipts use different populations, comparators, endpoints, and designs; without a head-to-head comparison, their estimates cannot be pooled or treated as causal evidence for a uniform effect. [R1] [R2] ## Falsifier A preregistered study in either source population, using that receipt's comparator and prespecified endpoint, would overturn this boundary if it showed a reproducible between-group benefit. [R1] [R2] ## Receipts - [R1] Metformin increases healthspan without a requirement for function of the insulin signaling pathway. (2015). DOI: 10.1371/journal.pone.0008758.g001. - [R2] Lung Function After Randomization to Metformin, Lifestyle Intervention or Placebo in the Diabetes Prevention Program Outcome Study (DPPOS) (2025). DOI: 10.1164/ajrccm.2025.211.abstracts.a4220. ## Status Receipt-bound alpha memo. Every factual claim is source-bound; the falsifier is a test, not evidence.
metadata
{
"article_type": "alpha_memo",
"domain_slug": "longevity_research",
"researka_object_type": "submission",
"researka_submission_id": "12fdbdc6-1161-4268-a0b3-646ebec6da06",
"title": "Metformin Findings Across Increases Healthspan Without Requirement Function and Lung Function Endpoints"
}